# An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma

> **NCT06015321** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 51 (estimated)

## Conditions studied

- Prostatic Adenocarcinoma

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT06015321
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-04-30
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015321, "An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06015321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*